Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted ...
From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...
Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...
TipRanks on MSN
Vizsla, Coty, Kalaris, Annexon, Brown & Brown trending
Analysts are intrested in these 5 stocks: ( ($VZLA) ), ( ($COTY) ), ( ($KLRS) ), ( ($ANNX) ) and ( ($BRO) ). Here is a breakdown of their recent ...
Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that ...
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...
Omeros (OMER) announced that the U.S. Food and Drug Administration, FDA, has approved YARTEMLE for the treatment of hematopoietic stem cell ...
Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...
Thinking outside the canon, and finding the gritty and the beautiful, within it. By Joshua Barone and Corinna da Fonseca-Wollheim JOSHUA BARONE Few art forms are as burdened by canons as classical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback